Avacta's pre|CISION Platform Reaches a Pivotal Moment with First Patient Dosed in Next-Gen Program
Fiscal 2025 results show acceleration as AVA6103 enters the clinic, dual-payload technology differentiates, and cash runway into 2027 underpins near-term catalysts.
AVCT.L · Earnings Call · 2026-05-25
From Promise to Proof: The First Patient Is In
When Christina Coughlin opened Avacta's fiscal 2025 results call with the words, "we're thrilled today to bring you our fiscal year 2025 preliminary results and a short business update," the tone was decidedly more confident than in prior quarters — and for good reason. The company's second-generation program, AVA6103, has officially entered the clinic. “We have -- we've delivered on that commitment that we made to dose the first patient on the FOCUS-01 trial in the first quarter of this year.” — Christina Coughlin, Management Team Member, likely CEO or similar executive role · 2026-05-25 This milestone transforms Avacta from a single-asset story into a true platform play, now with two oncology candidates in clinical development. The sustained-release chemistry that underpins AVA6103 was the centerpiece of the company's recent Science Day, where management contrasted the pre|CISION mechanism against established antibody-drug conjugates (ADCs). “The first is we see rapid tumor penetration with a pre|CISION molecule versus an ADC.” — Christina Coughlin, Management Team Member, likely CEO or similar executive role · 2026-05-25 This kinetic advantage is central to the thesis: by cleaving at the tumor's cancer-associated fibroblasts (CAFs) and releasing a high concentration of free payload directly into the tumor, the platform aims to widen the therapeutic window of potent but toxic cancer drugs.Dual Payload: A Unique Differentiator
The company has also advanced its third-generation dual-payload program, AVA6207. dual payload technology allows a single conjugate to deliver two different payloads (e.g., ATR and PARP inhibitors) — a capability that management believes is unmatched among non-ADC conjugates. In the Q&A, “We actually think we are the only drug conjugate company that can produce a non-ADC dual payload drug.” — Christina Coughlin, Management Team Member, likely CEO or similar executive role · 2026-05-25 This positions Avacta at the cutting edge of the broader ADC-like field, potentially appealing to partners seeking differentiated mechanisms. The company's sustained release mechanism, first revealed last year, is now being validated in the clinic. The clinical data from AVA6103 are expected by late 2026, and management remains committed to that timeline. As Coughlin noted, "We will be releasing all of the data together." The initial Phase I data will be a key inflection point for the platform's credibility.Financial Discipline and Partnering: The Same Tightrope
Financially, Avacta remains a classic development-stage biotech: no revenue, significant R&D spend, and a laser focus on cash management. “Net operating cash outflows from continuing operations was GBP 22.64 million as compared to GBP 24.94 million in 2024.” — Brian Hahn, Management Team Member, likely CFO or similar financial executive role · 2026-05-25 That improvement, combined with a recent GBP 10 million placing, extends the runway into early Q1 2027. CFO Brian Hahn was explicit: "The cash runway projection does not include any potential income from partnering." That is both a conservative stance and a subtle reminder that a deal could meaningfully extend the company's endurance. Partnering remains the central value unlock. Management has repeatedly said it will not start a pivotal trial for AVA6000 without a partner. In the current call, “Our position -- so really moving AVA6103 into the clinic was a big deal for us because our position in these partnering discussions is only getting stronger.” — Christina Coughlin, Management Team Member, likely CEO or similar executive role · 2026-05-25 This echoes prior commentary from the October 2025 call, where “We have committed that we won't start the further development activities in the absence of a partnership.” — Christina Coughlin, Chief Executive Officer · 2025-10-02 The consistency is reassuring, but the clock is ticking. The company also touched on the health authority interactions that have shaped its programs. The health authority removal of the lifetime maximum doxorubicin exposure — a critical regulatory win — was cited as a pivotal decision for AVA6000. This lifetime maximum removal directly improves the drug's potential for longer-duration therapy, especially in patients with prior anthracycline exposure.Reassessing the Pipeline: Affimers and Beyond
An important strategic shift was the announcement that the Affimer drug conjugate program (AVA70100) has been effectively held. Management explained that the clinical data from AVA6000 and the superior kinetics of the sustained-release platform have made the Affimer approach 'no longer needed' for targeting low-FAP tumors. "We don't think that there is the need for a larger biologic agent to facilitate that sustained release." This is a rational portfolio pruning that frees up capital and sharpens focus on the pre|CISION platform's competitive edge.And you know what, let me conclude, the future is so bright as we enter this transformative period of the next 9 to 12 months, and we really look forward to so many of those updates that we will be giving.